ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
10
views
0
references
Top references
cited by
87
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
4,207
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Author(s):
Pietro Perini
,
Sara Redaelli
,
M Marega
,
Frank Boschelli
,
R Rostagno
,
Vera Magistroni
,
Rocco Piazza
,
Carlo Gambacorti-Passerini
Publication date:
2009-01-20
Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Keywords:
Aniline Compounds
,
therapeutic use
,
Antineoplastic Agents
,
Benzamides
,
Drug Resistance, Neoplasm
,
Genes, abl
,
genetics
,
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
,
drug therapy
,
Mutation
,
Nitriles
,
Philadelphia Chromosome
,
Piperazines
,
Precursor Cell Lymphoblastic Leukemia-Lymphoma
,
Protein Kinase Inhibitors
,
Pyrimidines
,
Quinolines
,
Thiazoles
Read this article at
ScienceOpen
Publisher
PubMed
Further versions
open (via free pdf)
Powered by
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
AsiaChem
Author and article information
Journal
PubMed ID::
19075254
DOI::
10.1200/JCO.2008.19.8853
ScienceOpen disciplines:
Chemistry
Keywords:
Aniline Compounds
,
therapeutic use
,
Antineoplastic Agents
,
Benzamides
,
Drug Resistance, Neoplasm
,
Genes, abl
,
genetics
,
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
,
drug therapy
,
Mutation
,
Nitriles
,
Philadelphia Chromosome
,
Piperazines
,
Precursor Cell Lymphoblastic Leukemia-Lymphoma
,
Protein Kinase Inhibitors
,
Pyrimidines
,
Quinolines
,
Thiazoles
Data availability:
ScienceOpen disciplines:
Chemistry
Keywords:
Aniline Compounds
,
therapeutic use
,
Antineoplastic Agents
,
Benzamides
,
Drug Resistance, Neoplasm
,
Genes, abl
,
genetics
,
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
,
drug therapy
,
Mutation
,
Nitriles
,
Philadelphia Chromosome
,
Piperazines
,
Precursor Cell Lymphoblastic Leukemia-Lymphoma
,
Protein Kinase Inhibitors
,
Pyrimidines
,
Quinolines
,
Thiazoles
Comments
Comment on this article
Sign in to comment
scite_
Similar content
4,207
Activity of bosutinib by baseline and emergent mutation status in Philadelphia chromosome-positive leukemia patients with resistance or intolerance to other tyrosine kinase inhibitors [Abstract 110].
Authors:
H. J. Khoury
,
J. Cortes
,
C. Gambacorti-Passerini
…
Bosutinib as third-line therapy in patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) following failure with Imatinib plus Dasatinib and/or Nilotinib: 48-month update of a phase 1/2 study
Authors:
C Gambacorti Passerini
,
HJ Khoury
,
HM Kantarjian
…
An ongoing phase 3 study of Bosutinib versus Imatinib in patients with newly diagnosed chronic phase CML
Authors:
C Gambacorti Passerini
,
TH Brummendorf
,
I Dyagil
…
See all similar
Cited by
82
Kinase drug discovery 20 years after imatinib: progress and future directions
Authors:
Philip Cohen
,
Darren Cross
,
Pasi Jänne
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Authors:
Jorge E. Cortes
,
Carlo Gambacorti-Passerini
,
Michael Deininger
…
Response and Resistance to BCR-ABL1-Targeted Therapies
Authors:
Theodore P Braun
,
Christopher A. Eide
,
Brian J Druker
See all cited by